Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 May;46(5):1855-1865.
doi: 10.1177/0300060517752997. Epub 2018 Mar 19.

Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study

Qing Li  1 , Yan Ding  1 , Xu-Yin Zhang  1 , Wei-Wei Feng  1   2 , Ke-Qin Hua  1   2
Affiliations
Clinical Trial

Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study

Qing Li et al. J Int Med Res. 2018 May.

Abstract

Objective To provide novel insights into the clinical treatment of adenomyosis. Methods Two hundred patients with adenomyosis were enrolled in this prospective, nonrandomized, parallel-controlled study with a 1-year follow-up in our hospital. Group 1 was treated with 3.75 mg leuprorelin acetate (LA) (n = 40), Group 2 was treated with 1.88 mg LA (n = 40), Group 3 underwent Mirena implantation (n = 40), Group 4 underwent Mirena implantation after treatment with 3.75 mg LA (n = 40), Group 5 underwent Mirena implantation after treatment with 1.88 mg LA (n = 20), and Group 6 received San-Jie-Zhen-Tong capsules alone (n = 20). Uterine volume, pain, cancer antigen 125 level, ovary function, adverse effects, and Mirena expulsion were evaluated. Results The uterine volume and pain scores were lower in the groups treated with 1.88 than 3.75 mg LA, but the lower dose was associated with significantly fewer hot flashes and sweating. The 1-year Mirena expulsion rate was higher in Group 3 than in Groups 4 and 5 (10.00% vs. 3.33%, respectively). Costs were significantly higher in Groups 1 and 4 than in Groups 2 and 5. Conclusion Administration of 1.88 mg LA may be an alternative therapy for Asian patients with adenomyosis. The combination of LA and Mirena could enhance the therapeutic effect. Registration number: ChiCTR-IPR-15005971.

Keywords: Adenomyosis; Mirena; adverse effect; efficacy; gonadotropin-releasing hormone analogues; half-dose.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mean uterine volume in each group before and after treatment. Group 1, 3.75 mg leuprorelin acetate; Group 2, 1.88 mg leuprorelin acetate; Group 3, Mirena; Group 4, Mirena + 3.75 mg leuprorelin acetate; Group 5, Mirena + 1.88 mg leuprorelin acetate; Group 6, San-Jie-Zhen-Tong capsules
Figure 2.
Figure 2.
Changes in VAS scores in each group before and after treatment. VAS, visual analogue scale. Group 1, 3.75 mg leuprorelin acetate; Group 2, 1.88 mg leuprorelin acetate; Group 3, Mirena; Group 4, Mirena + 3.75 mg leuprorelin acetate; Group 5, Mirena + 1.88 mg leuprorelin acetate; Group 6, San-Jie-Zhen-Tong capsules
See this image and copyright information in PMC

References

    1. Struble J Reid S andBedaiwy MA.. Adenomyosis: a clinical review of a challenging gynecologic condition. J Minim Invasive Gynecol 2016; 23: 164–185. - PubMed
    1. Graziano A, Lo MG, Piva I, et al. Diagnostic findings in adenomyosis: a pictorial review on the major concerns. Eur Rev Med Pharmacol Sci 2015; 19: 1146–1154. - PubMed
    1. Levgur M, Abadi MA, Tucker A. Adenomyosis: symptoms, histology, and pregnancy terminations. Obstet Gynecol 2000; 95: 688–691. - PubMed
    1. Guo SW, Mao X, Ma Q, et al. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril 2013; 99: 231–240. - PubMed
    1. Morelli M, Rocca ML, Venturella R, et al. Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: a retrospective study. Gynecol Endocrinol 2013; 29: 305–308. - PubMed

Publication types

LinkOut - more resources